PharmGen Science, Inc. (004720.KS)
KRW 4065.0
(0.25%)
KRW 4065.0
(0.25%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 166.77 Billion KRW | 10.5% |
| 2022 | 150.93 Billion KRW | 37.38% |
| 2021 | 109.86 Billion KRW | 13.72% |
| 2020 | 96.61 Billion KRW | 1.55% |
| 2019 | 95.13 Billion KRW | 6.77% |
| 2018 | 89.1 Billion KRW | 11.52% |
| 2017 | 79.89 Billion KRW | 11.67% |
| 2016 | 71.54 Billion KRW | 18.44% |
| 2015 | 60.4 Billion KRW | 36.65% |
| 2014 | 44.2 Billion KRW | 13.43% |
| 2013 | 38.97 Billion KRW | 28.65% |
| 2012 | 30.29 Billion KRW | 8.53% |
| 2011 | 27.91 Billion KRW | -36.46% |
| 2010 | 43.92 Billion KRW | -9.88% |
| 2009 | 48.74 Billion KRW | -37.25% |
| 2008 | 77.68 Billion KRW | -1.12% |
| 2007 | 78.55 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 42.9 Billion KRW | 0.93% |
| 2024 Q1 | 42.5 Billion KRW | -8.67% |
| 2023 Q4 | 46.53 Billion KRW | 13.1% |
| 2023 Q1 | 37.59 Billion KRW | -3.37% |
| 2023 Q2 | 41.49 Billion KRW | 10.36% |
| 2023 Q3 | 41.14 Billion KRW | -0.83% |
| 2023 FY | 166.77 Billion KRW | 10.5% |
| 2022 Q4 | 38.9 Billion KRW | 7.17% |
| 2022 Q3 | 36.3 Billion KRW | 4.48% |
| 2022 Q2 | 34.74 Billion KRW | -15.18% |
| 2022 Q1 | 40.96 Billion KRW | 25.95% |
| 2022 FY | 150.93 Billion KRW | 37.38% |
| 2021 Q3 | 27.29 Billion KRW | 4.88% |
| 2021 Q2 | 26.02 Billion KRW | 8.39% |
| 2021 Q1 | 24.01 Billion KRW | -8.14% |
| 2021 FY | 109.86 Billion KRW | 13.72% |
| 2021 Q4 | 32.52 Billion KRW | 19.15% |
| 2020 Q2 | 23.84 Billion KRW | 3.83% |
| 2020 FY | 96.61 Billion KRW | 1.55% |
| 2020 Q4 | 26.14 Billion KRW | 10.47% |
| 2020 Q3 | 23.66 Billion KRW | -0.76% |
| 2020 Q1 | 22.96 Billion KRW | -3.57% |
| 2019 Q4 | 23.81 Billion KRW | 5.65% |
| 2019 Q2 | 25.55 Billion KRW | 10.03% |
| 2019 FY | 95.13 Billion KRW | 6.77% |
| 2019 Q1 | 23.22 Billion KRW | 1.47% |
| 2019 Q3 | 22.53 Billion KRW | -11.81% |
| 2018 Q4 | 22.88 Billion KRW | 1.62% |
| 2018 FY | 89.1 Billion KRW | 11.52% |
| 2018 Q2 | 22.28 Billion KRW | 4.1% |
| 2018 Q3 | 22.52 Billion KRW | 1.08% |
| 2018 Q1 | 21.4 Billion KRW | -0.86% |
| 2017 Q2 | 18.99 Billion KRW | -0.92% |
| 2017 FY | 79.89 Billion KRW | 11.67% |
| 2017 Q4 | 21.59 Billion KRW | 7.24% |
| 2017 Q3 | 20.13 Billion KRW | 5.99% |
| 2017 Q1 | 19.17 Billion KRW | 12.03% |
| 2016 Q1 | 18.72 Billion KRW | 9.51% |
| 2016 Q3 | 18.2 Billion KRW | 4.01% |
| 2016 Q4 | 17.11 Billion KRW | -5.99% |
| 2016 Q2 | 17.5 Billion KRW | -6.52% |
| 2016 FY | 71.54 Billion KRW | 18.44% |
| 2015 Q4 | 17.09 Billion KRW | 18.49% |
| 2015 FY | 60.4 Billion KRW | 36.65% |
| 2015 Q3 | 14.43 Billion KRW | -0.35% |
| 2015 Q2 | 14.48 Billion KRW | 0.61% |
| 2015 Q1 | 14.39 Billion KRW | 29.04% |
| 2014 Q3 | 11.26 Billion KRW | 0.8% |
| 2014 Q2 | 11.17 Billion KRW | 5.31% |
| 2014 FY | 44.2 Billion KRW | 13.43% |
| 2014 Q1 | 10.61 Billion KRW | 18.02% |
| 2014 Q4 | 11.15 Billion KRW | -0.97% |
| 2013 Q3 | 9.55 Billion KRW | -13.65% |
| 2013 Q4 | 8.99 Billion KRW | -5.87% |
| 2013 FY | 38.97 Billion KRW | 28.65% |
| 2013 Q1 | 9.36 Billion KRW | 33.58% |
| 2013 Q2 | 11.06 Billion KRW | 18.06% |
| 2012 Q4 | 7.01 Billion KRW | -15.28% |
| 2012 FY | 30.29 Billion KRW | 8.53% |
| 2012 Q2 | 7.21 Billion KRW | -7.38% |
| 2012 Q3 | 8.27 Billion KRW | 14.78% |
| 2012 Q1 | 7.78 Billion KRW | 26.05% |
| 2011 Q1 | 8.38 Billion KRW | -10.15% |
| 2011 Q4 | 6.17 Billion KRW | -13.57% |
| 2011 FY | 27.91 Billion KRW | -36.46% |
| 2011 Q2 | 6.2 Billion KRW | -26.02% |
| 2011 Q3 | 7.14 Billion KRW | 15.25% |
| 2010 Q3 | 9.07 Billion KRW | -29.37% |
| 2010 Q2 | 12.84 Billion KRW | 1.4% |
| 2010 Q1 | 12.67 Billion KRW | 268.16% |
| 2010 FY | 43.92 Billion KRW | -9.88% |
| 2010 Q4 | 9.33 Billion KRW | 2.81% |
| 2009 Q2 | 18.47 Billion KRW | 6.89% |
| 2009 Q4 | -7.53 Billion KRW | -136.71% |
| 2009 Q3 | 20.52 Billion KRW | 11.11% |
| 2009 Q1 | 17.28 Billion KRW | 1.09% |
| 2009 FY | 48.74 Billion KRW | -37.25% |
| 2008 Q1 | 23.93 Billion KRW | 46.8% |
| 2008 Q3 | 20.02 Billion KRW | 20.5% |
| 2008 Q4 | 17.09 Billion KRW | -14.65% |
| 2008 FY | 77.68 Billion KRW | -1.12% |
| 2008 Q2 | 16.62 Billion KRW | -30.56% |
| 2007 Q4 | 16.3 Billion KRW | -8.65% |
| 2007 Q2 | 20.11 Billion KRW | -17.17% |
| 2007 FY | 78.55 Billion KRW | 0.0% |
| 2007 Q3 | 17.84 Billion KRW | -11.28% |
| 2007 Q1 | 24.28 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Daewoong Co., Ltd. | 1815.1 Billion KRW | 90.812% |
| Wooridul Huebrain Limited | 55.75 Billion KRW | -199.154% |